Related to Fast Forward to Provide Funding for Concert’s MS Spasticity and Pain Candidate

• EU Approves Biogen Idec’s Avonex Intramuscular Autoinjector Product for MS
  
• Merck Serono Gives Up on Getting Drug Candidate for Multiple Sclerosis Approved
  
• Watson Invests $44M to Triple Capacity for Transdermal Patch and Topical Gel Manufacture
  
• Digna and Flamel Partner on Drug Delivery Formulations for Multiple Candidates
  
• Scientist Use UVB Skin Irradiation to Identify Potential New Target for Inflammatory Pain
  
• Sanofi and Genzyme Report Positive Data from Pivotal Trial Comparing Alemtuzumab with Rebif in MS
  
• Pfizer to Pay $49.8M for Icagen to Pad Focus on Pain Therapy
  
• EC Conditionally Approves Biogen Idec’s Multiple Sclerosis Drug Fampyra
  
• Researchers Find 29 New Genetic Variants Associated with Multiple Sclerosis
  
• Diamyd Shifts Development Focus from Diabetes to Pain and CNS Disorders
  
• Spinifex Secures A$18.25M for Phase II Pain Program
  
• NuPathe Shares Plunge After Launch of Migraine Patch Delayed
  
• Theralpha Wins €2.55M in Funding to Take Snake Venom Analgesic into Early Clinical Trials
  
• BioLineRx Gains Rights to Antipain Candidate from Tel Aviv University
  
• Target for Inflammatory and Neuropathic Pain Identified in Subset of Neurons
  
• Aestus Gains Rights to Prosidion’s Neuropathic Pain Drug and Expands Collaboration with ALS TDI
  
• Merck Serono Acquires Phase II-Ready Multiple Sclerosis Candidate Originally Developed by Peptimmune
  
• Japan Approves Novartis’ MS Drug Gilenya and CAPS Treatment Ilaris
  
• Merck Serono and Ono Sign Separate Agreements Worth $25M for MS and Cancer Drugs
  
• Sanofi and Genzyme Report Positive New Data from Phase III Multiple Sclerosis Study